Armstrong, A. J., Gingrich, J. R., Haggman, M., Stadler, W. M., Damber, J. E., Belkoff, L., … Pili, R. (2012). Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer. EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E126-U515.

Armstrong, A. J., J. R. Gingrich, M. Haggman, W. M. Stadler, J. E. Damber, L. Belkoff, R. Clark, et al. “Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer.” EUROPEAN UROLOGY SUPPLEMENTS 11, no. 1 (February 1, 2012): E126-U515.

Armstrong AJ, Gingrich JR, Haggman M, Stadler WM, Damber JE, Belkoff L, et al. Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer. EUROPEAN UROLOGY SUPPLEMENTS. 2012 Feb 1;11(1):E126-U515.

Armstrong, A. J., et al. “Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer.” EUROPEAN UROLOGY SUPPLEMENTS, vol. 11, no. 1, ELSEVIER SCIENCE BV, Feb. 2012, pp. E126-U515.

Armstrong AJ, Gingrich JR, Haggman M, Stadler WM, Damber JE, Belkoff L, Clark R, Brosman S, Nordle O, Forsberg G, Carducci MA, Pili R. Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer. EUROPEAN UROLOGY SUPPLEMENTS. ELSEVIER SCIENCE BV; 2012 Feb 1;11(1):E126-U515.